Ruiyun Zhang YOU? Author Swipe

Last 10y

Figure S1-S6 from Urinary Tumor DNA MRD Analysis to Identify Responders to Neoadjuvant Immunotherapy in Muscle-invasive Bladder Cancer Open

Ruiyun Zhang, Feng Xie, Akezhouli Shahatiaili, Guangyu Wu, Yue Zhang , et al. · 2025

Figure S1. (A) Representative MRI images for radiographic evaluation of neoadjuvant toripalimab. (B) Representative hematoxylin and eosin staining for histopathological evaluation of neoadjuvant toripalimab. CR = complete response; PR = pa…

Table S1-S8 from Urinary Tumor DNA MRD Analysis to Identify Responders to Neoadjuvant Immunotherapy in Muscle-invasive Bladder Cancer Open

Ruiyun Zhang, Jingyu Zang, Feng Xie, Guangyu Wu, Lu Zhang , et al. · 2025

Table S1. Clinicopathological characteristics of 20 patients in our study. Table S2. Representativeness of study participants. Table S3. Adverse events associated with toripalimab. Table S4. SNVs and InDels of therapy-naïve neoplastic tiss…

Disitamab vedotin combined with toripalimab and radiotherapy for multimodal organ-sparing treatment of muscle invasive bladder cancer: a proof-of-concept study Open

Lu Zhang, Di Jin, Jingyu Zang, Qian Lei, Tianxiang Zhang , et al. · 2025

These findings establish the feasibility, efficacy, and potential biomarker utility of a novel bladder-preserving regimen, setting the stage for a paradigm shift in MIBC management.

A case of Meckel’s diverticulum complicated with intestinal duplication: a case report Open

Peng Cai, Ruiyun Zhang, Tingting Zhang, Xianlan Xiang, Haowei Zhao , et al. · 2025

Resources Utilization Assessment and Cost-Minimization Analysis of the 6-Monthly Formulation of Triptorelin in the Treatment of Prostate Cancer in China Open

Y. Chen, Jiahua Pan, Yan Zhong, Bing Wu, Mengxia Yan , et al. · 2024

Compared to current 1-monthly and 3-monthly formulations, the 6-monthly GnRHa can reduce the total burden associated with prostate cancer treatment.

Case Report: A rare pediatric case of paraneoplastic pemphigus associated with Castleman disease misdiagnosed as Behçets disease Open

Ranran Zhang, Jia Liu, Nana Nie, Dahai Wang, Jie Wu , et al. · 2024

Castleman disease (CD) is a rare lymphoproliferative disease known as angiofollicular lymph node hyperplasia, firstly reported in 1954. It mainly occurs in adults, presenting with a wide range of clinical manifestations, including paraneop…

Supplementary Figure S7 from Genomic Profiling and Immune Phenotyping of Neuroendocrine Bladder Cancer Open

Jingyu Zang, Akezhouli Shahatiaili, Mei‐Chun Cai, Di Jin, Peiye Shen , et al. · 2024

Gene expression and immune repertoire in NEBC.

Supplementary Figure S2 from Genomic Profiling and Immune Phenotyping of Neuroendocrine Bladder Cancer Open

Jingyu Zang, Akezhouli Shahatiaili, Mei‐Chun Cai, Di Jin, Peiye Shen , et al. · 2024

p53 expression and mutational landscape in NEBC.

Supplementary Figure S10 from Genomic Profiling and Immune Phenotyping of Neuroendocrine Bladder Cancer Open

Jingyu Zang, Akezhouli Shahatiaili, Mei‐Chun Cai, Di Jin, Peiye Shen , et al. · 2024

Radiographic evaluation and survival analysis in NEBC and UBC.

Supplementary Table S1-S10 from Genomic Profiling and Immune Phenotyping of Neuroendocrine Bladder Cancer Open

Jingyu Zang, Akezhouli Shahatiaili, Mei‐Chun Cai, Di Jin, Peiye Shen , et al. · 2024

Table S1. Quality control of sequencing data. Table S2. Representativeness of study participants. Table S3. Clinicopathological characteristics of 35 patients diagnosed with NEBC. Table S4. Summary of clinicopathological characteristics fo…

Supplementary Figure S6 from Genomic Profiling and Immune Phenotyping of Neuroendocrine Bladder Cancer Open

Jingyu Zang, Akezhouli Shahatiaili, Mei‐Chun Cai, Di Jin, Peiye Shen , et al. · 2024

Tumor purity, ploidy, and CNVs in NEBC.

Supplementary Figure S4 from Genomic Profiling and Immune Phenotyping of Neuroendocrine Bladder Cancer Open

Jingyu Zang, Akezhouli Shahatiaili, Mei‐Chun Cai, Di Jin, Peiye Shen , et al. · 2024

Kataegis events in NEBC.

Data from Genomic Profiling and Immune Phenotyping of Neuroendocrine Bladder Cancer Open

Jingyu Zang, Akezhouli Shahatiaili, Mei‐Chun Cai, Di Jin, Peiye Shen , et al. · 2024

Purpose:Neuroendocrine bladder cancer (NEBC) poses a formidable clinical challenge and attracts keen interests to explore immunotherapy as a viable treatment option. However, a comprehensive immunogenomic landscape has yet to be thoroughly…

Supplementary Figure S9 from Genomic Profiling and Immune Phenotyping of Neuroendocrine Bladder Cancer Open

Jingyu Zang, Akezhouli Shahatiaili, Mei‐Chun Cai, Di Jin, Peiye Shen , et al. · 2024

Immunotype distribution and fibrotic barriers in NEBC.

Supplementary Figure S5 from Genomic Profiling and Immune Phenotyping of Neuroendocrine Bladder Cancer Open

Jingyu Zang, Akezhouli Shahatiaili, Mei‐Chun Cai, Di Jin, Peiye Shen , et al. · 2024

Chromoplexy events in NEBC.

Supplementary Figure S1 from Genomic Profiling and Immune Phenotyping of Neuroendocrine Bladder Cancer Open

Jingyu Zang, Akezhouli Shahatiaili, Mei‐Chun Cai, Di Jin, Peiye Shen , et al. · 2024

Histopathological characteristics of NEBC and survival analysis in NEBC and UBC.

Supplementary Figure S3 from Genomic Profiling and Immune Phenotyping of Neuroendocrine Bladder Cancer Open

Jingyu Zang, Akezhouli Shahatiaili, Mei‐Chun Cai, Di Jin, Peiye Shen , et al. · 2024

NMF analysis of NEBC mutational signatures.

Supplementary Figure S8 from Genomic Profiling and Immune Phenotyping of Neuroendocrine Bladder Cancer Open

Jingyu Zang, Akezhouli Shahatiaili, Mei‐Chun Cai, Di Jin, Peiye Shen , et al. · 2024

Survival outcomes by immunotype in NEBC.

Figure S1-S6 from Urinary tumor DNA MRD analysis to identify responders to neoadjuvant immunotherapy in muscle-invasive bladder cancer Open

Ruiyun Zhang, Jingyu Zang, Di Jin, Feng Xie, Akezhouli Shahatiaili , et al. · 2024

Figure S1. (A) Representative MRI images for radiographic evaluation of neoadjuvant toripalimab. (B) Representative hematoxylin and eosin staining for histopathological evaluation of neoadjuvant toripalimab. CR = complete response; PR = pa…

Supplementary Information 1 from Urinary tumor DNA MRD analysis to identify responders to neoadjuvant immunotherapy in muscle-invasive bladder cancer Open

Ruiyun Zhang, Jingyu Zang, Di Jin, Feng Xie, Akezhouli Shahatiaili , et al. · 2024

Supplementary methods and clinical trial protocol

Table S1-S8 from Urinary tumor DNA MRD analysis to identify responders to neoadjuvant immunotherapy in muscle-invasive bladder cancer Open

Ruiyun Zhang, Jingyu Zang, Di Jin, Feng Xie, Akezhouli Shahatiaili , et al. · 2024

Table S1. Clinicopathological characteristics of 20 patients in our study. Table S2. Representativeness of study participants. Table S3. Adverse events associated with toripalimab. Table S4. SNVs and InDels of therapy-naïve neoplastic tiss…

Table S1-S8 from Urinary tumor DNA MRD analysis to identify responders to neoadjuvant immunotherapy in muscle-invasive bladder cancer Open

Ruiyun Zhang, Jingyu Zang, Di Jin, Feng Xie, Akezhouli Shahatiaili , et al. · 2024

Table S1. Clinicopathological characteristics of 20 patients in our study. Table S2. Representativeness of study participants. Table S3. Adverse events associated with toripalimab. Table S4. SNVs and InDels of therapy-naïve neoplastic tiss…

Figure S1-S6 from Urinary tumor DNA MRD analysis to identify responders to neoadjuvant immunotherapy in muscle-invasive bladder cancer Open

Ruiyun Zhang, Jingyu Zang, Di Jin, Feng Xie, Akezhouli Shahatiaili , et al. · 2024

Figure S1. (A) Representative MRI images for radiographic evaluation of neoadjuvant toripalimab. (B) Representative hematoxylin and eosin staining for histopathological evaluation of neoadjuvant toripalimab. CR = complete response; PR = pa…

Data from Urinary tumor DNA MRD analysis to identify responders to neoadjuvant immunotherapy in muscle-invasive bladder cancer Open

Ruiyun Zhang, Jingyu Zang, Di Jin, Feng Xie, Akezhouli Shahatiaili , et al. · 2024

Purpose: Bladder preservation is a viable option for some muscle-invasive bladder cancer (MIBC) patients, but an effective noninvasive biomarker test to accurately identify promising candidates is lacking. Here we present the clinical appl…

Supplementary Information 1 from Urinary tumor DNA MRD analysis to identify responders to neoadjuvant immunotherapy in muscle-invasive bladder cancer Open

Ruiyun Zhang, Jingyu Zang, Di Jin, Feng Xie, Akezhouli Shahatiaili , et al. · 2024

Supplementary methods and clinical trial protocol

Pre-Op Hydronephrosis Predicts Outcomes in Patients Receiving Robot-Assisted Radical Cystectomy Open

Chris Ho-Ming Wong, Ivan Ching‐Ho Ko, David Leung, Seok Ho Kang, K. Kitamura , et al. · 2024

Introduction: Robot-assisted radical cystectomy (RARC) has gained momentum in the management of muscle invasive bladder cancer (MIBC). Predictors of RARC outcomes are not thoroughly studied. We aim to investigate the implications of preope…

Long-Term Outcomes of Orthotopic Neobladder Versus Ileal Conduit Urinary Diversion in Robot-Assisted Radical Cystectomy (RARC): Multicenter Results from the Asian RARC Consortium Open

Chris Ho-ming Wong, Ivan Ching-ho Ko, Seok Ho Kang, K. Kitamura, Shigeo Horie , et al. · 2024

Purpose Robot-assisted radical cystectomy (RARC) has gained traction in the management of muscle invasive bladder cancer. Urinary diversion for RARC was achieved with orthotopic neobladder and ileal conduit. Evidence on the optimal method …

The Value of Dual Time Point 18F-FDG PET/CT Imaging in Differentiating Lymph Node Metastasis From Reactive Hyperplasia in Bladder Urothelial Carcinoma Open

Xiang Zhou, Zehua Lu, Ruixue Zhang, Ruiyun Zhang, Gang Huang , et al. · 2024

Synergistic induction of tertiary lymphoid structures by chemoimmunotherapy in bladder cancer Open

Lu Zhang, Ruiyun Zhang, Di Jin, Tianxiang Zhang, Akezhouli Shahatiaili , et al. · 2024

Quality Evaluation of Clinical Practice Guidelines and the Recommendations for Esophageal Cancer Open

Peizan Ni, Ruiyun Zhang, Xiaohui Wang, Xuan Wu, Hong Ge · 2024

Background: In the process of diagnosis and treatment of esophageal cancer, the clinical guidelines is of great significance for the medical behavior of clinicians and application of new research results. However, a non-standard formulatio…

Fetching topic information...